SCHEMBL3869981

SCHEMBL3869981

Cc1cc(C)c2oc(Nc3ccc(-c4cn(Cc5ccc(NC(=O)NCCO)cc5)c5ncnc(N)c45)cc3)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 19/20 0.49
▸ KDR P35968 2/20 0.48
▸ PLK4 O00444 1/20 0.45
▸ MAPK13 O15264 1/20 0.45
▸ PDPK1 O15530 1/20 0.45
▸ DAPK3 O43293 1/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ RPS6KA5 O75582 1/20 0.45
▸ MAP4K4 O95819 1/20 0.45
▸ PAK4 O96013 1/20 0.45
▸ ABL1 P00519 1/20 0.45
▸ EGFR P00533 1/20 0.45
▸ NTRK1 P04629 1/20 0.45
▸ INSR P06213 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ FYN P06241 1/20 0.45
▸ CDK1 P06493 1/20 0.45
▸ FES P07332 1/20 0.45
▸ CSF1R P07333 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3821663 0.88 KDR (0.55) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL6109831 0.85 KDR (0.51) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL3849725 0.84 KDR (0.51) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL6108287 0.81 KDR (0.52) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL3817980 0.80 KDR (0.55) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL3822847 0.79 KDR (0.56) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL3812024 0.76 KDR (0.55) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL6110001 0.73 KDR (0.53) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL6108968 0.73 EGFR (0.56) FLT3KDRPLK4MAPK13PDPK1
SCHEMBL6110004 0.73 KDR (0.53) FLT3KDRPLK4MAPK13PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730148-A4 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LAB (US) 2009-08-19 — — EP disclosed
EP-1730148-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2006-12-13 — — EP disclosed
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABBOTT LABORATORIES 2006-02-02 — — US disclosed
WO-2005074603-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABL1, MAP3K19, MAP3K20 FLT3 102/4885KDR 2441/4885PLK4 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback